PARP7-IN-14 (I-1) is a potent and selective PARP7 inhibitor with an IC₅₀ value of 7.6 nM. PARP7-IN-14 has anticancer activity.

PARP7-IN-14 (I-1) 作用于 CT26 细胞的 MTT IC₅₀ 值为 12.85 μM，具有一定的肿瘤抗增殖作用。
PARP7-IN-14 (I-1)(0-4 μM)可促进 CT26 细胞系中 IFN-β 和 CXCL10 的 mRNA 表达水平并诱导 STAT1 磷酸化浓度依赖性增加。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

PARP7-IN-14 (I-1)(p.o., 25-100 mg/kg, twice daily, 14 days) 在 CT26 荷瘤小鼠中, 可以明显抑制剂肿瘤生长，与对照组相比，用 I-1 处理的小鼠平均肿瘤体积减少了 67%，且不会导致体重减轻或其他毒性迹象。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

PARP7-IN-14 (I-1)(p.o., 25-100 mg/kg, twice daily, 14 days) 在 CT26 荷瘤小鼠中, 可以明显抑制剂肿瘤生长，与对照组相比，用 I-1 处理的小鼠平均肿瘤体积减少了 67%，且不会导致体重减轻或其他毒性迹象。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Hongfeng Gu, et al. Discovery of the Potent and Highly Selective PARP7 Inhibitor as a Novel Immunotherapeutic Agent for Tumors. J Med Chem. 2023 Jan 12;66(1):473-490.   [Content Brief]